{"id":"lansoprazole-od","safety":{"commonSideEffects":[{"rate":"12-15%","effect":"Headache"},{"rate":"8-10%","effect":"Diarrhea"},{"rate":"5-8%","effect":"Abdominal pain"},{"rate":"4-6%","effect":"Nausea"},{"rate":"3-5%","effect":"Constipation"},{"rate":null,"effect":"Vitamin B12 deficiency (with long-term use)"}]},"_chembl":{"chemblId":"CHEMBL480","moleculeType":"Small molecule","molecularWeight":"369.37"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lansoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and inactivates the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells. This blocks the final step of gastric acid production, significantly reducing both basal and stimulated acid secretion. It is used to treat acid-related gastrointestinal disorders by maintaining elevated gastric pH.","oneSentence":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:48.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Zollinger-Ellison syndrome"},{"name":"Prevention of NSAID-induced ulcers"}]},"trialDetails":[{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT06894992","phase":"NA","title":"Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment","status":"RECRUITING","sponsor":"Mario Steffanus","startDate":"2025-05-01","conditions":"Peptic Ulcer Bleeding","enrollment":162},{"nctId":"NCT06778824","phase":"NA","title":"Neuroregulators for the Treatment of Diseases Associated With Esophageal-brain-gut Axis Communication Abnormalities.","status":"RECRUITING","sponsor":"Hualien Tzu Chi General Hospital","startDate":"2024-04-02","conditions":"Gut-Brain Disorders, GERD Without Erosive Esophagitis","enrollment":610},{"nctId":"NCT03087162","phase":"PHASE4","title":"Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori","status":"COMPLETED","sponsor":"Ramathibodi Hospital","startDate":"2017-01-01","conditions":"H Pylori Eradication","enrollment":180},{"nctId":"NCT03418337","phase":"NA","title":"Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD","status":"UNKNOWN","sponsor":"Taipei Veterans General Hospital, Taiwan","startDate":"2017-08-01","conditions":"Compare the Response Rate of Atypical GERD After PPI Therapy","enrollment":120},{"nctId":"NCT02099682","phase":"","title":"Long-term Use of Takepron Capsules on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Low-dose Aspirin","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-08","conditions":"Gastric or Duodenal Ulcers","enrollment":3366},{"nctId":"NCT02099708","phase":"","title":"Long-term Use of Takepron on the Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-10","conditions":"Gastric or Duodenal Ulcers","enrollment":3502},{"nctId":"NCT02726269","phase":"PHASE3","title":"Triple Therapy Versus Levofloxacin-based Therapy for Helicobacter Pylori Eradication in Mexico.","status":"COMPLETED","sponsor":"Asofarma de México S.A de C.V.","startDate":"2012-06","conditions":"Helicobacter Pylori Gastritis","enrollment":230},{"nctId":"NCT02703896","phase":"PHASE4","title":"Prophylaxis for Aspiration of Gastric Contents.","status":"COMPLETED","sponsor":"King Saud University","startDate":"2012-01","conditions":"Pulmonary Aspiration of Gastric Contents","enrollment":1920},{"nctId":"NCT02064907","phase":"PHASE1","title":"Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Bioavailability","enrollment":52},{"nctId":"NCT02096458","phase":"PHASE1","title":"Sensory Evaluation of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Gastroesophageal Reflux Disease, Erosive Esophagitis, Heartburn","enrollment":8},{"nctId":"NCT00708149","phase":"PHASE4","title":"Comparison of the Efficacy for Stress Ulcer Prophylaxis Between the Patients Received Lansoprazole OD and Control Group Weaning From Mechanical Ventilator in Respiratory Care Center: a Randomized Control Trial","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2009-06","conditions":"Respiratory Failure","enrollment":120},{"nctId":"NCT01182597","phase":"PHASE3","title":"Oral Versus IV Proton Pump Inhibitor in High-risk Bleeding Peptic Ulcers After Endoscopic Hemostasis","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2010-08","conditions":"Peptic Ulcers","enrollment":190}],"_emaApprovals":[],"_faersSignals":[{"count":55,"reaction":"PYREXIA"},{"count":50,"reaction":"INTERSTITIAL LUNG DISEASE"},{"count":36,"reaction":"DECREASED APPETITE"},{"count":35,"reaction":"DIARRHOEA"},{"count":32,"reaction":"PNEUMONIA"},{"count":25,"reaction":"HEPATIC FUNCTION ABNORMAL"},{"count":24,"reaction":"VOMITING"},{"count":22,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":20,"reaction":"CEREBRAL INFARCTION"},{"count":19,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Takepron OD for PO QD"],"phase":"marketed","status":"active","brandName":"lansoprazole OD","genericName":"lansoprazole OD","companyName":"Far Eastern Memorial Hospital","companyId":"far-eastern-memorial-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lansoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Zollinger-Ellison syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}